{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Table 8 - List of pharmacokinetic parameters and definitions', 'Parameters', 'Drug/Analyte', 'Matrix', 'Definition/Calculation', 'Cmax', 'Alemtuzumab', 'Serum', 'Maximum serum concentration observed', 'Tmax', 'Alemtuzumab', 'Serum', 'Time to reach Cmax', 'Alemtuzumab', 'Serum', 'AUClast', 'Area under the cumulative serum concentration versus time curve', 'calculated using the trapezoidal method from time zero to the real time tlast', 'Alemtuzumab', 'Serum', 'Area under the cumulative serum concentration versus time curve', 'extrapolated to infinity according to the following equation:', 'AUC', 'AUC = last + AZ last', 'Values with percentage of extrapolation >30% will not be reported', 'Alemtuzumab', 'Serum', 'Terminal half-life associated with the terminal slope (Az) determined', 'according to the following equation:', '0.693', '11/2z', 't 1/2Z = Az', 'where AZ is the slope of the regression line of the terminal phase of the', 'cumulative serum concentration versus time curve, in semi-logarithmic', 'scale. Half-life is calculated by taking the regression of at least 3 points.', '9.2.2.2 Pharmacodynamic variables', 'Pharmacodynamic assessments of lymphocyte subsets will be performed in order to characterize', 'the PD profile of 2 treatment courses of alemtuzumab in paediatric patients.', '9.2.2.2.1 Assessment methods', 'Lymphocyte phenotyping', 'To monitor the extent of lymphocyte depletion and repopulation, lymphocyte phenotyping,', 'including a standard, 6-color TBNK (T cells, B cells, and natural killer cells) panel (CD3+, CD4+,', 'CD8+, CD19+, CD16+, CD56+, total lymphocytes, and helper/suppressor ratio [CD4+/CD8+]),', 'will be performed. Lymphocyte phenotyping will be assessed at screening, D-14 to D-7, M1, M4,', 'M8, M12, M13, M15, M18, M21, M24/at EOTP; annually in Safety Monitoring Phase.', '9.2.2.3 Quality of life endpoints', 'Quality of Life (QoL) will be assessed by established generic paediatric QoL measures.', 'PedsQL questionnaire', 'The PedsQL\u2122 Measurement Model is a modular approach to measuring health-related', 'quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic', 'Property of the Sanofi Group - strictly confidential', 'Page 57', 'VV-CLIN-0254406 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'health conditions. The PedsQL Measurement Model integrates seamlessly both generic core', 'scales and disease-specific modules into one measurement system.', 'The 23-item PedsQL Generic Core Scales (Appendix F) were designed to measure the core', 'dimensions of health as delineated by the World Health Organization, as well as role (school)', 'functioning.', 'Paediatric NeuroQoL questionnaire', 'Paediatric NeuroQoL (Quality of Life in Neurological Disorders) is a measurement system that', 'evaluates and monitors the physical, mental, and social effects experienced by children living with', 'neurological conditions. Physical effects (fatigue and pain) and mental effects (cognitive function,', 'anxiety, and depression) experienced by patients will be assessed (Appendix G).', 'PedsQL and paediatric NeuroQoL questionnaire will be assessed at Screening, D-14 to D-7, M4,', 'M8, M12, M18, M24/at EOTP; and annually in Safety Monitoring Phase.', '9.3', 'SAFETY ENDPOINTS', 'Safety endpoints will be assessed by:', 'AE reporting at each visit.', 'Physical examination and vital signs: Screening, D-14 to D-7, M0/D1, M4, M8, M12,', 'M15, M18, M21, M24/at EOTP; every 6 months in the safety monitoring phase, and at', 'every relapse visit.', 'Additionally, vital signs will be collected hourly during alemtuzumab infusion and post', 'infusion observation period.', 'Clinical chemistry laboratories: Screening, D-14 to D-7, M4, M8, M12, M15, M18, M21,', 'M24/at EOTP; quarterly in the safety monitoring phase. In addition, only serum creatinine', 'will be assessed at M0/D1, monthly in alemtuzumab treatment phase (Year 1 and 2);', 'monthly in the safety monitoring phase (inclusive of chemistry panel).', 'Hematology: Screening, D-14 to D -7, M0/D1, and monthly in alemtuzumab treatment', 'phase (Year 1 and 2); EOTP, and monthly in the safety monitoring phase.', 'Urinalysis: Screening, D-14 to D -7, monthly in alemtuzumab treatment phase (Year 1 and', '2); EOTP, and monthly in the safety monitoring phase.', 'Thyroid Function tests: Screening, D-14 to D -7, quarterly in alemtuzumab treatment', 'phase (Year 1 and 2); EOTP, and quarterly in the safety monitoring phase.', 'Tanner staging: Screening, M12, M24/at EOTP; annually in the safety monitoring phase.', 'Pregnancy testing (females only): Screening (blood test), D-14 to D -7 and M12 (urine', 'test).', 'Assessment of ADA: M0/D1 (baseline), post dose M1, M3, M12 (prenext dose), M13,', 'M15, M24/at EOTP; and annually in the safety monitoring phase.', 'Property of the Sanofi Group - strictly confidential', 'Page 58', 'VV-CLIN-02544065.0']\n\n###\n\n", "completion": "END"}